Tousignant Jennifer 4

4 · Viridian Therapeutics, Inc.\DE · Filed Mar 4, 2026

Form 4

Period: 2026-03-02

Chief Legal Officer

Transactions

Exercise/Conversion
Common Stock
[F2]
2026-03-03+5,169→ 5,169 total
Tax Payment
Common Stock
2026-03-03$29.32/sh−1,724$50,548→ 3,445 total
Award
Stock Option (Right to Buy)
[F1]
2026-03-02+119,300→ 119,300 total
Exercise: $30.25Exp: 2036-03-02→ Common Stock (119,300 underlying)
Award
Restricted Stock Units
[F2][F3]
2026-03-02+23,850→ 23,850 total
→ Common Stock (23,850 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F4]
2026-03-03−5,169→ 15,510 total
→ Common Stock (5,169 underlying)

Footnotes (4)

[F1]The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.
[F2]Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.
[F3]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.
[F4]The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

Signature

Jennifer Tousignant|2026-03-04

Documents

1 file